Effect of ABCB1 Polymorphisms and Atorvastatin on Sitagliptin Pharmacokinetics in Healthy Volunteers

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2013 Feb 15

PMID 23407853

Citations 8

Authors

Christina L Aquilante

Michael F Wempe

Maha S Sidhom

Lisa A Kosmiski

Julie A Predhomme

Affiliations

Soon will be listed here.

Abstract

Objectives: The objectives of this study were to determine if ABCB1 polymorphisms are associated with interindividual variability in sitagliptin pharmacokinetics and if atorvastatin alters the pharmacokinetic disposition of sitagliptin in healthy volunteers.

Methods: In this open-label, randomized, two-phase crossover study, healthy volunteers were prospectively stratified according to ABCB1 1236/2677/3435 diplotype (n = 9, CGC/CGC; n = 10, CGC/TTT; n = 10, TTT/TTT). In one phase, participants received a single 100 mg dose of sitagliptin; in the other phase, participants received 40 mg of atorvastatin for 5 days, with a single 100 mg dose of sitagliptin administered on day 5. A 24-h pharmacokinetic study followed each sitagliptin dose, and the study phases were separated by a 14-day washout period.

Results: Sitagliptin pharmacokinetic parameters did not differ significantly between ABCB1 CGC/CGC, CGC/TTT, and TTT/TTT diplotype groups during the monotherapy phase. Atorvastatin administration did not significantly affect sitagliptin pharmacokinetics, with geometric mean ratios (90 % confidence intervals) for sitagliptin maximum plasma concentration, plasma concentration-time curve from zero to infinity, renal clearance, and fraction of sitagliptin excreted unchanged in the urine of 0.93 (0.86-1.01), 0.96 (0.91-1.01), 1.02 (0.93-1.12), and 0.98 (0.90-1.06), respectively.

Conclusions: ABCB1 CGC/CGC, CGC/TTT, and TTT/TTT diplotypes did not influence sitagliptin pharmacokinetics in healthy volunteers. Furthermore, atorvastatin had no effect on the pharmacokinetics of sitagliptin in the setting of ABCB1 CGC/CGC, CGC/TTT, and TTT/TTT diplotypes.

Citing Articles

Rosuvastatin-Induced Rhabdomyolysis as a Result of Drug Interaction With Sitagliptin: A Case Report.

Atapour A, Momenzadeh M, Panahishokouh M, Badri S Clin Med Insights Case Rep. 2024; 17:11795476241274162.

PMID: 39224482 PMC: 11367606. DOI: 10.1177/11795476241274162.

Common SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject.

Hwang J, Jeong S, Kim Y, Lee Y, Ji S, Lee S Transl Clin Pharmacol. 2023; 30(4):212-225.

PMID: 36632075 PMC: 9810488. DOI: 10.12793/tcp.2022.30.e23.

Lipophilic vs. hydrophilic statins and psychiatric hospitalizations and emergency room visits in US Veterans with schizophrenia and bipolar disorder.

Postolache T, Medoff D, Brown C, Fang L, Upadhyaya S, Lowry C Pteridines. 2021; 32(1):48-69.

PMID: 34887622 PMC: 8654264. DOI: 10.1515/pteridines-2020-0028.

Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.

Nasykhova Y, Tonyan Z, Mikhailova A, Danilova M, Glotov A Int J Mol Sci. 2020; 21(18).

PMID: 32961860 PMC: 7555942. DOI: 10.3390/ijms21186842.

The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial.

Leon-Cachon R, Bamford A, Meester I, Barrera-Saldana H, Gomez-Silva M, Garcia Bustos M Sci Rep. 2020; 10(1):8900.

PMID: 32483134 PMC: 7264171. DOI: 10.1038/s41598-020-65843-y.

References

Kimchi-Sarfaty C, Oh J, Kim I, Sauna Z, Calcagno A, Ambudkar S . A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2006; 315(5811):525-8. DOI: 10.1126/science.1135308. View

Hoffmeyer S, Burk O, von Richter O, Arnold H, Brockmoller J, Johne A . Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000; 97(7):3473-8. PMC: 16264. DOI: 10.1073/pnas.97.7.3473. View

Herman G, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M . Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005; 78(6):675-88. DOI: 10.1016/j.clpt.2005.09.002. View

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart J, Haffner S . Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006; 29(6):1220-6. DOI: 10.2337/dc05-2465. View

Chinn L, Kroetz D . ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther. 2007; 81(2):265-9. DOI: 10.1038/sj.clpt.6100052. View

Hochman J, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin J . Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004; 21(9):1686-91. DOI: 10.1023/b:pham.0000041466.84653.8c. View

Wang D, Johnson A, Papp A, Kroetz D, Sadee W . Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005; 15(10):693-704. View

Bergman A, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M . Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006; 28(1):55-72. DOI: 10.1016/j.clinthera.2006.01.015. View

Colhoun H, Betteridge D, Durrington P, Hitman G, Neil H, Livingstone S . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435):685-96. DOI: 10.1016/S0140-6736(04)16895-5. View

10.

Kao D, Kohrt H, Kugler J . Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med. 2008; 25(10):1229-30. PMC: 2602841. DOI: 10.1111/j.1464-5491.2008.02536.x. View

11.

Scheen A . Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010; 12(8):648-58. DOI: 10.1111/j.1463-1326.2010.01212.x. View

12.

Sever P, Poulter N, Dahlof B, Wedel H, Collins R, Beevers G . Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005; 28(5):1151-7. DOI: 10.2337/diacare.28.5.1151. View

13.

Hodges L, Markova S, Chinn L, Gow J, Kroetz D, Klein T . Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2010; 21(3):152-61. PMC: 3098758. DOI: 10.1097/FPC.0b013e3283385a1c. View

14.

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004; 44(3):720-32. DOI: 10.1016/j.jacc.2004.07.001. View

15.

Boyd R, STERN R, STEWART B, Wu X, Reyner E, Zegarac E . Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000; 40(1):91-8. DOI: 10.1177/00912700022008612. View

16.

Choi D, Shin W, Choi J . Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. Eur J Clin Pharmacol. 2008; 64(5):445-9. DOI: 10.1007/s00228-007-0447-5. View

17.

Lee Y, Lee M, Lim L, Jang S, Chung J . Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther. 2009; 48(1):36-45. DOI: 10.5414/cpp48036. View

18.

Bhome R, Penn H . Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction. Diabet Med. 2011; 29(5):693-4. DOI: 10.1111/j.1464-5491.2011.03502.x. View

19.

Wu X, Whitfield L, STEWART B . Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res. 2000; 17(2):209-15. DOI: 10.1023/a:1007525616017. View

20.

Wang E, Casciano C, Clement R, Johnson W . HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001; 18(6):800-6. DOI: 10.1023/a:1011036428972. View